Jörn M. Schattenberg

31.8k total citations · 6 hit papers
332 papers, 9.2k citations indexed

About

Jörn M. Schattenberg is a scholar working on Epidemiology, Hepatology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Jörn M. Schattenberg has authored 332 papers receiving a total of 9.2k indexed citations (citations by other indexed papers that have themselves been cited), including 240 papers in Epidemiology, 154 papers in Hepatology and 69 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Jörn M. Schattenberg's work include Liver Disease Diagnosis and Treatment (229 papers), Liver Disease and Transplantation (88 papers) and Diet, Metabolism, and Disease (61 papers). Jörn M. Schattenberg is often cited by papers focused on Liver Disease Diagnosis and Treatment (229 papers), Liver Disease and Transplantation (88 papers) and Diet, Metabolism, and Disease (61 papers). Jörn M. Schattenberg collaborates with scholars based in Germany, United States and United Kingdom. Jörn M. Schattenberg's co-authors include Peter R. Galle, Quentin M. Anstee, Mark J. Czaja, Christian Labenz, Marcus Schuchmann, Nadine Gehrke, Detlef Schuppan, Yvonne Huber, Raina M. Rigoli and Saleh A. Alqahtani and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

Jörn M. Schattenberg

302 papers receiving 9.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

2020 681 citations Hannes Hagström, Jörn M. Schattenberg et al. profile →
Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis

2016 581 citations Stuart McPherson, Timothy Hardy et al. The American Journal of Gastroenterology profile →
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial

2023 282 citations Rohit Loomba, Eric Lawitz et al. profile →
Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis

2020 255 citations Jörn M. Schattenberg et al. profile →
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis

2024 217 citations Arun J. Sanyal, Pierre Bédossa et al. New England Journal of Medicine profile →
A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures

2023 73 citations Dina Tiniakos, Jörn M. Schattenberg et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jörn M. Schattenberg Germany	50	6.7k	3.4k	2.5k	1.6k	1.5k	332	9.2k
Mazen Noureddin United States	49	7.1k 1.1×	3.9k 1.1×	2.7k 1.0×	1.3k 0.8×	1.3k 0.9×	272	9.1k
Sven Francque Belgium	48	7.3k 1.1×	3.2k 0.9×	2.9k 1.1×	1.5k 0.9×	1.5k 1.0×	194	9.1k
Naim Alkhouri United States	59	8.7k 1.3×	3.8k 1.1×	3.9k 1.5×	1.7k 1.1×	1.9k 1.3×	325	11.2k
Jian‐Gao Fan China	48	7.5k 1.1×	3.0k 0.9×	2.8k 1.1×	3.0k 1.9×	1.1k 0.7×	200	10.6k
Pegah Golabi United States	37	6.2k 0.9×	2.9k 0.8×	2.6k 1.0×	975 0.6×	1.0k 0.7×	106	7.5k
Helena Cortez‐Pinto Portugal	45	7.7k 1.2×	3.0k 0.9×	3.1k 1.2×	1.9k 1.2×	1.2k 0.8×	138	10.0k
Frank A. Anania United States	44	5.7k 0.8×	2.6k 0.8×	2.1k 0.8×	2.3k 1.4×	1.7k 1.1×	81	8.7k
Kathleen E. Corey United States	44	4.8k 0.7×	2.5k 0.7×	1.9k 0.8×	962 0.6×	1.3k 0.9×	167	7.0k
Takumi Kawaguchi Japan	45	4.2k 0.6×	2.9k 0.9×	1.6k 0.6×	2.2k 1.4×	1.6k 1.0×	290	8.4k
Anna Alisi Italy	56	6.6k 1.0×	1.9k 0.6×	3.4k 1.3×	2.7k 1.7×	1.5k 1.0×	225	9.8k

Countries citing papers authored by Jörn M. Schattenberg

Since Specialization

Citations

This map shows the geographic impact of Jörn M. Schattenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jörn M. Schattenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jörn M. Schattenberg more than expected).

Fields of papers citing papers by Jörn M. Schattenberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jörn M. Schattenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jörn M. Schattenberg. The network helps show where Jörn M. Schattenberg may publish in the future.

Co-authorship network of co-authors of Jörn M. Schattenberg

This figure shows the co-authorship network connecting the top 25 collaborators of Jörn M. Schattenberg. A scholar is included among the top collaborators of Jörn M. Schattenberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jörn M. Schattenberg. Jörn M. Schattenberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Petroff, David, Jörn M. Schattenberg, S Zeuzem, et al.. (2025). Evaluating Resmetirom Eligibility Among Patients with MASH: Insights from the German Steatotic Liver Disease-Registry. Zeitschrift für Gastroenterologie. 63(8). 836–843. 1 indexed citations

Huber, Yvonne, Jürgen H. Prochaska, Thomas Koeck, et al.. (2025). Incidence of Major Cardiovascular Events in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease in the General Population. European Journal of Heart Failure. 27(11). 2490–2500.

Younossi, Zobair M., Homie Razavi, Michael S. Sherman, et al.. (2025). Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction‐Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective. Alimentary Pharmacology & Therapeutics. 61(9). 1467–1478. 8 indexed citations

Sanyal, Arun J., Pierre Bédossa, Mandy Fraessdorf, et al.. (2024). A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. New England Journal of Medicine. 391(4). 311–319. 217 indexed citations breakdown →

mann, Esther M. Hoff, Karl J. Lackner, Thomas Münzel, et al.. (2024). Change of Intraocular Pressure Over 5 Years and its Relationship to Cardiovascular Parameters: Results From the Gutenberg Health Study. Investigative Ophthalmology & Visual Science. 65(1). 12–12. 3 indexed citations

Schemmerer, Mathias, Hans H. Bock, Jörn M. Schattenberg, et al.. (2024). Proof of infectivity of hepatitis E virus particles from the ejaculate of chronically infected patients. Journal of Medical Virology. 96(6). e29735–e29735. 3 indexed citations

Schattenberg, Jörn M., Naga Chalasani, & Naim Alkhouri. (2023). Artificial Intelligence Applications in Hepatology. Clinical Gastroenterology and Hepatology. 21(8). 2015–2025. 21 indexed citations

Lawitz, Eric, Thomas Reiberger, Jörn M. Schattenberg, et al.. (2023). Safety and pharmacokinetics of BI 685509, a soluble guanylyl cyclase activator, in patients with cirrhosis: A randomized Phase Ib study. Hepatology Communications. 7(11). 8 indexed citations

Boeckmans, Joost, Laurent Sandrin, Christian Knackstedt, & Jörn M. Schattenberg. (2023). Liver stiffness as a cornerstone in heart disease risk assessment. Liver International. 44(2). 344–356. 11 indexed citations

10.

Harrison, Stephen A., Vlad Ratziu, Quentin M. Anstee, et al.. (2023). Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics. 59(1). 51–63. 56 indexed citations

11.

Teufel, Andreas, Andreas Geier, Christoph Sarrazin, et al.. (2023). Intersektorales Management von Patienten mit unklarer Leberwerterhöhung und nichtalkoholischer Fettlebererkrankung (NAFLD). Zeitschrift für Gastroenterologie. 61(8). 1028–1036. 1 indexed citations

12.

Nagel, Michael, Peter R. Galle, Jörn M. Schattenberg, et al.. (2023). Validation of the CLIF-C OF Score and CLIF-C ACLF Score to Predict Transplant-Free Survival in Patients with Liver Cirrhosis and Concomitant Need for Intensive Care Unit Treatment. Medicina. 59(5). 866–866. 3 indexed citations

13.

Gairing, Simon Johannes, Lukáš Müller, Christian Labenz, et al.. (2022). Bevacizumab in combination with octreotide rescues a patient with liver cirrhosis, GAVE syndrome and refractory hemorrhage – a case report. Zeitschrift für Gastroenterologie. 61(3). 275–279. 2 indexed citations

14.

John, Katharina, Martin Franck, Monika Rau, et al.. (2022). Non-Invasive Detection of Fibrotic NASH in NAFLD Patients with Low or Intermediate FIB-4. Journal of Clinical Medicine. 11(15). 4394–4394. 7 indexed citations

15.

Lazarus, Jeffrey V., Henry E. Mark, Massimo Colombo, et al.. (2021). A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. Alimentary Pharmacology & Therapeutics. 55(2). 234–243. 8 indexed citations

16.

Schattenberg, Jörn M., Albert Parés, Kris V. Kowdley, et al.. (2021). A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. Journal of Hepatology. 74(6). 1344–1354. 125 indexed citations

17.

Graf, Christiana, Christian M. Lange, Katharina Willuweit, et al.. (2021). Hepatic sarcoidosis: Clinical characteristics and outcome. JHEP Reports. 3(6). 100360–100360. 16 indexed citations

18.

Labenz, Christian, Gerrit Toenges, Yvonne Huber, et al.. (2019). Raised serum Interleukin‐6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy. Alimentary Pharmacology & Therapeutics. 50(10). 1112–1119. 38 indexed citations

19.

Labenz, Christian, Sandra Koch, Yvonne Huber, et al.. (2017). Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. Digestive Diseases. 36(1). 78–88. 7 indexed citations

20.

McPherson, Stuart, Timothy Hardy, Jean‐François Dufour, et al.. (2016). Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. The American Journal of Gastroenterology. 112(5). 740–751. 581 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact